Caicun Zhou
周彩存
MD, PhD
Director, Department of Medical Oncology肿瘤科主任
👥Biography 个人简介
Dr. Caicun Zhou leads lung cancer immunotherapy research at Shanghai Pulmonary Hospital, one of China's highest-volume thoracic oncology centers. He has directed major immunotherapy trials generating Chinese-specific efficacy data and has been instrumental in integrating immunotherapy into standard Chinese lung cancer protocols.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lung Cancer Immunotherapy
Led multiple phase III trials of PD-1/PD-L1 inhibitors in Chinese NSCLC patients, generating landmark data that supported NMPA approvals for immunotherapy indications.
Chinese NSCLC Data
Developed comprehensive real-world and clinical trial datasets characterizing immunotherapy efficacy and biomarkers specific to Chinese NSCLC populations.
Combination Strategies
Pioneered chemo-immunotherapy combination regimens in Chinese patients, establishing optimal dosing and sequencing strategies incorporated into national guidelines.
Representative Works 代表性著作
Camrelizumab versus placebo in combination with chemotherapy for NSCLC (CameL)
Journal of Clinical Oncology (2021)
Demonstrated significant PFS improvement with camrelizumab plus chemotherapy in advanced non-squamous NSCLC, supporting first-line immunotherapy in China.
Sugemalimab versus placebo in EGFR-mutated NSCLC after TKI failure
Nature Medicine (2022)
Explored PD-L1 blockade in TKI-resistant EGFR-mutated NSCLC, clarifying immunotherapy's role in this challenging patient population.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 周彩存 的研究动态
Follow Caicun Zhou's research updates
留下邮箱，当我们发布与 Caicun Zhou（Shanghai Pulmonary Hospital, Tongji University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment